Shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) have been given a consensus advice of “Average Purchase” by the seven brokerages which are presently masking the corporate, Marketbeat Ratings reviews. Two analysis analysts have rated the inventory with a maintain ranking and 4 have assigned a purchase ranking to the corporate. The typical 12 month goal value amongst brokers which have coated the inventory within the final 12 months is $11.17.
GRPH has been the topic of numerous analyst reviews. Cantor Fitzgerald initiated protection on shares of Graphite Bio in a analysis be aware on Thursday, September fifteenth. They set an “obese” ranking and a $12.00 goal value for the corporate. Financial institution of America decreased their value goal on Graphite Bio from $10.00 to $8.00 in a report on Tuesday.
Institutional Inflows and Outflows
Hedge funds have not too long ago made modifications to their positions within the inventory. BlackRock Inc. lifted its place in Graphite Bio by 39.8% within the first quarter. BlackRock Inc. now owns 1,694,506 shares of the corporate’s inventory price $8,642,000 after buying a further 482,238 shares throughout the interval. EcoR1 Capital LLC boosted its stake in Graphite Bio by 36.1% throughout the third quarter. EcoR1 Capital LLC now owns 1,582,135 shares of the corporate’s inventory valued at $5,015,000 after shopping for a further 419,956 shares within the final quarter. Vanguard Group Inc. grew its holdings in Graphite Bio by 71.7% throughout the first quarter. Vanguard Group Inc. now owns 1,202,755 shares of the corporate’s inventory price $6,135,000 after buying a further 502,381 shares throughout the interval. Renaissance Applied sciences LLC purchased a brand new stake in Graphite Bio within the second quarter price about $2,165,000. Lastly, Laurion Capital Administration LP acquired a brand new stake in Graphite Bio within the 2nd quarter valued at about $1,577,000. Institutional traders and hedge funds personal 52.51% of the corporate’s inventory.
Graphite Bio Buying and selling Down 1.1 %
NASDAQ:GRPH opened at $2.82 on Tuesday. The agency has a market capitalization of $163.98 million, a PE ratio of -1.60 and a beta of 0.44. Graphite Bio has a 52 week low of $2.07 and a 52 week excessive of $13.39. The inventory has a 50 day shifting common of $3.35 and a 200-day shifting common of $3.27.
Graphite Bio (NASDAQ:GRPH – Get Rating) final issued its earnings outcomes on Wednesday, November ninth. The corporate reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.04. As a bunch, analysts predict that Graphite Bio will submit -1.88 EPS for the present fiscal 12 months.
Graphite Bio Firm Profile
Graphite Bio, Inc, a clinical-stage gene enhancing firm, engages in growing therapies for critical and life-threatening ailments in the USA. It presents GPH101, a gene-edited autologous hematopoietic stem cell product candidate to instantly right the mutation that causes sickle cell illness and restore regular grownup hemoglobin expression; GPH201 for the therapy of X-linked extreme mixed immunodeficiency syndrome; and GPH301, a product candidate for the therapy of Gaucher illness, a genetic dysfunction that ends in a deficiency within the glucocerebrosidase enzyme.
This on the spot information alert was generated by narrative science know-how and monetary knowledge from MarketBeat with a purpose to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to email@example.com.
Earlier than you think about Graphite Bio, you may wish to hear this.
MarketBeat retains monitor of Wall Road’s top-rated and greatest performing analysis analysts and the shares they advocate to their shoppers each day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Graphite Bio wasn’t on the listing.
Whereas Graphite Bio presently has a “Average Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.